He cant give an opinion since he doesnt know anything about it
The pathway for compounded GLP-1s has not closed entirely: legitimate patient-specific 503A compounding, with individualized clinical documentation, at the four-prescription safe harbor ceiling, remains legally available for genuine edge cases such as documented allergies to branded product excipients
Many people feel the medication working well before they see major changes on the scale
& Alvrez, V
Thus, in perfect agreement with the recent ADA-EASD consensus report [6], we also encourage the adoption of GLP-1RA plus SGLT2i combination therapy in T2DM patients with established ASCVD (coronary artery disease, cerebrovascular disease, or peripheral arterial disease) or multiple risk factors for ASCVD (i.e., age 55 years, obesity, dyslipidemia, hypertension, current tobacco use, left ventricular hypertrophy, and/or proteinuria) whose HbA1c remains suboptimal despite initial treatment with only one of these agents
